Sepsis, September 27 edition

Using septic acute lung injury patient samples, mouse models, and macrophage-specific manipulation, the study identified LAPTM5 as a key regulator of macrophage autophagic homeostasis. LAPTM5 links PGAM5 to VAMP8, promotes PGAM5-dependent VAMP8 dephosphorylation and autophagosome–lysosome fusion, thereby clearing damaged mitochondria and reducing oxidative stress and inflammation.

Impact: This study provides a mechanistically coherent, multi-level explanation for how defective macrophage autophagy amplifies septic lung injury and identifies LAPTM5 as a potentially actionable therapeutic target. Its use of patient samples, cell-specific genetics, and in vivo rescue strengthens biological plausibility.

Clinical Implications: LAPTM5 expression or the associated autophagy pathway could eventually support risk stratification or targeted therapy for septic acute lung injury. Translation is currently preclinical; no change to standard sepsis or acute lung injury treatment is justified yet.

Future Directions: Future work should develop pharmacologic or genetic strategies to enhance LAPTM5 activity, validate the pathway in independent human cohorts, and determine whether LAPTM5-based interventions improve survival without impairing antimicrobial host defense.

This integrative study combined genetic causal inference, transcriptomics, single-cell RNA sequencing, and prospective clinical validation to nominate TYMP as a protective immunoregulatory marker in sepsis. Higher plasma TYMP levels were observed in survivors, and TYMP showed modest prognostic discrimination for 28-day mortality, with TYMP-expressing CD4-positive T cells linked to hypoxia- and TGFB1-related immunoregulatory programs.

Impact: The paper moves beyond nonspecific inflammatory biomarkers by linking a candidate marker to a defined immune-cell population and genetic evidence. It provides a testable framework for precision immunophenotyping in sepsis, although the clinical cohort is small and exploratory.

Clinical Implications: TYMP could eventually be evaluated as a prognostic biomarker or as a means of identifying patients with preserved immunoregulatory capacity. Its clinical use requires validation in larger, diverse cohorts and comparison with established severity scores and biomarkers.

Future Directions: Larger multicenter cohorts should validate TYMP independently, assess incremental value beyond SOFA and established biomarkers, and test whether TYMP identifies biologically distinct sepsis endotypes that respond differently to immunomodulatory treatment.

In 169 liver transplant recipients with ICU-acquired multidrug-resistant Gram-negative infection, ceftazidime-avibactam was associated with higher clinical response and microbiological eradication than colistin-meropenem. Sepsis-related mortality was also lower with ceftazidime-avibactam, but 30-day all-cause mortality did not differ, and the observational design limits causal interpretation.

Impact: This study addresses a high-risk population for whom randomized evidence is difficult to obtain and compares two clinically important treatment strategies. The large difference in response and sepsis-related mortality supports prospective evaluation, while the absence of an all-cause mortality benefit appropriately limits the strength of the conclusion.

Clinical Implications: When microbiologically appropriate, ceftazidime-avibactam may be preferred over colistin-meropenem for ICU-acquired multidrug-resistant Gram-negative infections in liver transplant recipients, particularly when treatment toxicity and clinical response are concerns. Local resistance patterns, susceptibility testing, renal function, and stewardship principles remain essential.

Future Directions: Prospective multicenter studies should compare susceptibility-guided ceftazidime-avibactam with optimized alternative regimens, incorporate nephrotoxicity and quality-of-life outcomes, and evaluate mortality using adequately powered designs and standardized treatment protocols.